TA-CIN
Phase 1Biologic
TA-CIN is one of 42 biologic programs targeting Treatment. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
332 competitors in Treatment
#DrugCompanyPhaseTrials
1Biltricide
BayerPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Niclocide
BayerPreclinical
Minipress
PfizerPreclinical
Theo-Dur
PfizerPreclinical
Levulan
Sun Pharmaceutical Industries, Inc.Preclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Intuniv
PPromius Pharma, LLC
Preclinical
Crixivan
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Somavert
PPharmacia and Upjohn
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cervical Cancer1 trial
Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02405221·15 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TA-CIN. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details